{"id":403144,"date":"2010-03-08T09:52:38","date_gmt":"2010-03-08T14:52:38","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=67193"},"modified":"2010-03-08T09:52:38","modified_gmt":"2010-03-08T14:52:38","slug":"roche-biogen-halt-arthritis-study","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/403144","title":{"rendered":"Roche, Biogen Halt Arthritis Study"},"content":{"rendered":"\n<div style=\"text-transform:uppercase\"><a href=\"http:\/\/www.xconomy.com\/tag\/Biotech\/\">Biotech<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/arthritis\/\">Arthritis<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/Drugs\/\">Drugs<\/a><\/div>\n<p>\t\t<strong>Luke Timmerman wrote:<\/strong><\/p>\n<p>Roche and Cambridge, MA-based Biogen Idec are halting development of an experimental drug for rheumatoid arthritis because of safety concerns, according a <a href=\"http:\/\/www.businessweek.com\/news\/2010-03-08\/roche-biogen-idec-suspend-tests-for-arthritis-drug-update2-.html\">report<\/a> today by Bloomberg News. The drug, ocrelizumab, was designed to hit the same protein target on cells as the hit antibody ritxumimab, (Rituxan), albeit in a form thought to be more conducive for chronic autoimmune diseases than rituximab, which was originally developed as a cancer drug. Still, the new medicine was linked to &#8220;serious and opportunistic infections,&#8221; some of which were fatal, Basel, Switzerland-based Roche said today in an e-mailed statement cited by Bloomberg. The drug is still being tested for multiple sclerosis, according to the Bloomberg report.<\/p>\n<div class=\"postFooter\"><a href=\"http:\/\/www.xconomy.com\/boston\/2010\/03\/08\/roche-biogen-halt-arthritis-study\/#comments\">Comments<\/a> | <a href=http:\/\/www.xconomy.com\/reprints\/>Reprints<\/a> | Share: &nbsp;<br \/>\n<a href=\"http:\/\/twitter.com\/home?status=RT%20@Xconomy%20Roche,%20Biogen%20Halt%20Arthritis%20Study%20http:\/\/xconomy.com\/?p=67193\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/twitter.gif\" alt=\"Retweet\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/www.facebook.com\/sharer.php?u=http:\/\/www.xconomy.com\/boston\/2010\/03\/08\/roche-biogen-halt-arthritis-study\/&#038;t=Roche,%20Biogen%20Halt%20Arthritis%20Study\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/facebook.gif\" alt=\"Facebook\"\/><\/a><br \/>\n&nbsp;<a href=http:\/\/www.xconomy.com\/boston\/2010\/03\/08\/roche-biogen-halt-arthritis-study\/email\/  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/email.gif\" alt=\"Email\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/sharethis.com\/item?publisher=bfda184d-6684-4f7a-a23f-ca4ed4db9287&amp;title=Roche%2C+Biogen+Halt+Arthritis+Study&amp;url=http%3A%2F%2Fwww.xconomy.com%2Fboston%2F2010%2F03%2F08%2Froche-biogen-halt-arthritis-study%2F\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/share.gif\" alt=\"Share\"\/><\/a>\n<\/div>\n<p>\t     \t\t<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<a href=\"http:\/\/ads.pheedo.com\/click.phdo?s=de722e348ff5bb91820353c728c6a358&#038;p=1\"><img decoding=\"async\" alt=\"\" style=\"border: 0;\" border=\"0\" src=\"http:\/\/ads.pheedo.com\/img.phdo?s=de722e348ff5bb91820353c728c6a358&#038;p=1\"\/><\/a><br \/>\n<img loading=\"lazy\" decoding=\"async\" alt=\"\" height=\"0\" width=\"0\" border=\"0\" style=\"display:none\" src=\"http:\/\/a.rfihub.com\/eus.gif?eui=2218\"\/><\/p>\n<p><a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/hEb-xB2DgS2eEwdQ16zjli9Mxis\/0\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/hEb-xB2DgS2eEwdQ16zjli9Mxis\/0\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><br \/>\n<a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/hEb-xB2DgS2eEwdQ16zjli9Mxis\/1\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/hEb-xB2DgS2eEwdQ16zjli9Mxis\/1\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/Xconomy_Full\/~4\/b-Hlu2tp7aI\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biotech, Arthritis, Drugs Luke Timmerman wrote: Roche and Cambridge, MA-based Biogen Idec are halting development of an experimental drug for rheumatoid arthritis because of safety concerns, according a report today by Bloomberg News. The drug, ocrelizumab, was designed to hit the same protein target on cells as the hit antibody ritxumimab, (Rituxan), albeit in a [&hellip;]<\/p>\n","protected":false},"author":1192,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-403144","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/403144","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1192"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=403144"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/403144\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=403144"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=403144"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=403144"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}